Latest news and press releases about Nanobiotix S.A. (NBTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles.
Price
| Price | $35.72 |
| Market Cap | $1.8B |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | -15.69 |
| EV / EBITDA | -140.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 31.23% |
| Return on Invested Capital | -74.29% |
| Return on Assets | -35.36% |
| Gross Margin | 100.00% |
| Operating Margin | -36.49% |
| Net Margin | -80.83% |
Related companies: ABUS · EYPT · GHRS · KURA · LENZ · PROK · RZLT
Explore sector: Healthcare · Biotechnology
More sections of NBTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks